Targeting the Notch pathway: Twists and turns on the road to rational therapeutics

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages 2418-2420

  Aster, Jon C ^a   Blacklow, Stephen C ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; SEMAGACESTAT;

ALZHEIMER DISEASE; ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84864005158     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.0992     Document Type: Review

References (36)

1. South AP, Cho RJ, Aster JC: The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol [epub ahead of print on January 30, 2012]
2. Phng LK, Gerhardt H: Angiogenesis: A team effort coordinated by notch. Dev Cell 16:196-208, 2009
3. Radtke F, Fasnacht N, Macdonald HR: Notch signaling in the immune system. Immunity 32:14-27, 2010
4. Kumano K, Chiba S, Kunisato A, et al: Notch1 but not Notch2 is essential for generating hematopoietic stem cells from endothelial cells. Immunity 18:699-711, 2003 (Pubitemid 36588586)
5. Yoon K, Gaiano N: Notch signaling in the mammalian central nervous system: Insights from mouse mutants. Nat Neurosci 8:709-715, 2005 (Pubitemid 43085834)
6. Ables JL, Breunig JJ, Eisch AJ, et al: Not(ch) just development: Notch signalling in the adult brain. Nat Rev Neurosci 12:269-283, 2011
7. Nicolas M, Wolfer A, Raj K, et al: Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33:416-421, 2003 (Pubitemid 36278861)
8. Proweller A, Tu L, Lepore JJ, et al: Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res 66:7438-7444, 2006 (Pubitemid 44289196)
9. Wang NJ, Sanborn Z, Arnett KL, et al: Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 108:17761-17766, 2011
10. Stransky N, Egloff AM, Tward AD, et al: The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157-1160, 2011
11. Agrawal N, Frederick MJ, Pickering CR, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333:1154-1157, 2011
12. Liu Z, Turkoz A, Jackson EN, et al: Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest 121:800-808, 2011
13. Klinakis A, Lobry C, Abdel-Wahab O, et al: A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 473:230-233, 2011
14. DeAngelo DJ, Stone RM, Silverman LB, et al: A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lympho- blastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 24:6585, 2006
15. Tolcher AW, Messersmith WA, Mikulski SM, et al: Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol 30:2348-2353, 2012
16. Fouladi M, Stewart CF, Olson J, et al: Phase I trial of MK-0752 in children with refractory CNS malignancies: A pediatric brain tumor consortium study. J Clin Oncol 29:3529-3534, 2011
17. Kopan R, Ilagan MX: The canonical Notch signaling pathway: Unfolding the activation mechanism. Cell 137:216-233, 2009
18. Levitan D, Greenwald I: Facilitation of lin-12-mediated signalling by sel-12, a Caenorhabditis elegans S182 Alzheimer's disease gene. Nature 377: 351-354, 1995
19. Extance A: Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 9:749-751, 2010
20. Murakami D, Okamoto I, Nagano O, et al: Presenilin-dependent gamma-secretase activity mediates the intramembranous cleavage of CD44. Oncogene 22:1511-1516, 2003 (Pubitemid 36390600)
21. Lammich S, Okochi M, Takeda M, et al: Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. J Biol Chem 277:44754-44759, 2002 (Pubitemid 36159067)
22. Wong GT, Manfra D, Poulet FM, et al: Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876-12882, 2004 (Pubitemid 38445862)
23. van Es JH, van Gijn ME, Riccio O, et al: Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435:959-963, 2005 (Pubitemid 40896322)
24. Riccio O, van Gijn ME, Bezdek AC, et al: Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep 9:377-383, 2008
25. Wu Y, Cain-Hom C, Choy L, et al: Therapeutic antibody targeting of individual Notch receptors. Nature 464:1052-1057, 2010
26. Li K, Li Y, Wu W, et al: Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J Biol Chem 283:8046-8054, 2008
27. Ridgway J, Zhang G, Wu Y, et al: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083-1087, 2006 (Pubitemid 46018529)
28. Yan M: Therapeutic promises and challenges of targeting DLL4/NOTCH1. Vasc Cell 3:17, 2011
29. Ellisen LW, Bird J, West DC, et al: TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66:649-661, 1991 (Pubitemid 121001701)
30. Robinson DR, Kalyana-Sundaram S, Wu YM, et al: Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 17:1646-1651, 2011
31. Moellering RE, Cornejo M, Davis TN, et al: Direct inhibition of the NOTCH transcription factor complex. Nature 462:182-188, 2009
32. Kridel R, Meissner B, Rogic S, et al: Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119:1963-1971, 2012
33. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al: C-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20:2096-2109, 2006 (Pubitemid 44157460)
34. Dang CV, Le A, Gao P: MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15:6479-6483, 2009
35. Bedogni B, Warneke JA, Nickoloff BJ, et al: Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 118:3660-3670, 2008
36. Balint K, Xiao M, Pinnix CC, et al: Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 115:3166-3176, 2005 (Pubitemid 41567581)